Camp4 Therapeutics Corp
CAMP
Company Profile
Business description
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
Contact
One Kendall Square
Building 1400 West, 3rd Floor
CambridgeMA02139
USAT: +1 617 651-8867
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
48
Stocks News & Analysis
stocks
ASX retail share remains cheap despite weaker earnings
Weaker profit result drives cut to fair value yet shares remain undervalued.
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.70 | 16.80 | -0.19% |
| CAC 40 | 7,846.55 | 102.63 | 1.33% |
| DAX 40 | 22,957.08 | 320.17 | 1.41% |
| Dow JONES (US) | 46,429.49 | 305.43 | 0.66% |
| FTSE 100 | 10,106.84 | 141.68 | 1.42% |
| HKSE | 25,335.95 | 272.24 | 1.09% |
| NASDAQ | 21,929.82 | 167.93 | 0.77% |
| Nikkei 225 | 53,749.62 | 1,497.34 | 2.87% |
| NZX 50 Index | 13,050.98 | 121.68 | 0.94% |
| S&P 500 | 6,591.90 | 35.53 | 0.54% |
| S&P/ASX 200 | 8,537.00 | 10.00 | -0.12% |
| SSE Composite Index | 3,931.84 | 50.56 | 1.30% |